Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), has appointed Nishant Saxena as Chief Financial Officer, effective January 15, 2025. Saxena brings over 20 years of experience in finance, strategy, capital markets, M&A, and corporate development. He previously served as Managing Director at Evercore's healthcare group, where he advised on transactions exceeding $500 billion in total value.
In his 15+ years at Evercore, Saxena led numerous client engagements including mergers, IPOs, private placements, and structured financings. He holds both a B.S. in Economics and an MBA from the Wharton School. The appointment comes as Jeune prepares to advance its lead program into Phase 2 later in 2025, building on promising KB301 Phase 1 data in addressing aged skin treatments.
Jeune Aesthetics, una filiale di Krystal Biotech (NASDAQ: KRYS), ha nominato Nishant Saxena come Chief Financial Officer, con effetto dal 15 gennaio 2025. Saxena porta con sé oltre 20 anni di esperienza in finanza, strategia, mercati dei capitali, fusioni e acquisizioni, e sviluppo aziendale. In precedenza, ha ricoperto il ruolo di Managing Director nel gruppo sanitario di Evercore, dove ha fornito consulenza su transazioni per un valore totale superiore a 500 miliardi di dollari.
Nei suoi oltre 15 anni in Evercore, Saxena ha gestito numerosi incarichi con i clienti, inclusi fusioni, IPO, collocamenti privati e finanziamenti strutturati. Ha conseguito sia una laurea in economia che un MBA presso la Wharton School. Questa nomina avviene mentre Jeune si prepara a far avanzare il suo programma principale nella Fase 2 entro la fine del 2025, basandosi sui promettenti dati della Fase 1 di KB301 per il trattamento della pelle invecchiata.
Jeune Aesthetics, una filial de Krystal Biotech (NASDAQ: KRYS), ha nombrado a Nishant Saxena como Director Financiero, con efecto a partir del 15 de enero de 2025. Saxena aporta más de 20 años de experiencia en finanzas, estrategia, mercados de capitales, fusiones y adquisiciones, y desarrollo corporativo. Anteriormente, se desempeñó como Director General en el grupo de atención médica de Evercore, donde asesoró en transacciones que superaron los 500 mil millones de dólares en valor total.
Durante sus más de 15 años en Evercore, Saxena lideró numerosos compromisos con clientes, incluidas fusiones, ofertas públicas iniciales, colocaciones privadas y financiamientos estructurados. Posee tanto una licenciatura en Economía como un MBA de la Wharton School. Esta nominación llega mientras Jeune se prepara para avanzar su programa principal a la Fase 2 a finales de 2025, basándose en los prometedores datos de la Fase 1 de KB301 en el tratamiento de la piel envejecida.
Jeune Aesthetics는 Krystal Biotech (NASDAQ: KRYS)의 자회사로서 Nishant Saxena를 최고 재무 책임자로 임명했습니다. 임기는 2025년 1월 15일부터 시작됩니다. Saxena는 재무, 전략, 자본 시장, 인수 합병 및 기업 개발 분야에서 20년 이상의 경험을 보유하고 있습니다. 그는 이전에 Evercore의 헬스케어 그룹에서 임원으로 근무하며 5천억 달러 이상의 거래에 대한 자문을 제공했습니다.
Evercore에서의 15년 이상 동안 Saxena는 인수 합병, IPO, 사모 배정 및 구조화된 금융을 포함한 여러 고객 프로젝트를 이끌었습니다. 그는 와튼 스쿨에서 경제학 학사 및 MBA를 취득했습니다. 이번 임명은 Jeune가 2025년 후반에 2단계로 주요 프로그램을 발전시킬 준비를 하면서, 노화 피부 치료를 위한 KB301 1단계 데이터에서 기대되는 성과를 바탕으로 이루어집니다.
Jeune Aesthetics, une filiale de Krystal Biotech (NASDAQ: KRYS), a nommé Nishant Saxena au poste de directeur financier, à compter du 15 janvier 2025. Saxena apporte plus de 20 ans d'expérience dans les domaines de la finance, de la stratégie, des marchés de capitaux, des fusions et acquisitions, et du développement corporate. Auparavant, il était directeur général dans le groupe santé d'Evercore, où il a conseillé sur des transactions dépassant les 500 milliards de dollars en valeur totale.
Au cours de ses plus de 15 ans chez Evercore, Saxena a dirigé de nombreux engagements clients, y compris des fusions, des IPO, des placements privés et des financements structurés. Il détient à la fois un B.S. en économie et un MBA de la Wharton School. Cette nomination intervient alors que Jeune se prépare à faire avancer son programme phare vers la phase 2 plus tard en 2025, s'appuyant sur les données prometteuses de la phase 1 de KB301 dans le traitement de la peau vieillissante.
Jeune Aesthetics, eine Tochtergesellschaft von Krystal Biotech (NASDAQ: KRYS), hat Nishant Saxena zum Chief Financial Officer ernannt, mit Wirkung zum 15. Januar 2025. Saxena bringt über 20 Jahre Erfahrung in den Bereichen Finanzen, Strategie, Kapitalmärkte, Fusionen und Übernahmen sowie Unternehmensentwicklung mit. Zuvor war er als Managing Director in der Healthcare-Gruppe von Evercore tätig, wo er bei Transaktionen mit einem Gesamtwert von über 500 Milliarden Dollar beratend tätig war.
In seinen über 15 Jahren bei Evercore leitete Saxena zahlreiche Kundenengagements, darunter Fusionen, IPOs, Privatplatzierungen und strukturierte Finanzierungen. Er hat sowohl einen B.S. in Economics als auch einen MBA von der Wharton School. Die Ernennung erfolgt, während Jeune sich darauf vorbereitet, sein Hauptprogramm Ende 2025 in die Phase 2 zu überführen, gestützt auf vielversprechende Daten aus Phase 1 von KB301 zur Behandlung alternder Haut.
- Appointment of experienced CFO with over 20 years in finance and healthcare
- New CFO brings substantial M&A experience ($500B+ in transaction value)
- Company advancing to Phase 2 trials in 2025
- Positive Phase 1 data for lead product KB301
- None.
PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore’s healthcare group, where he advised on transactions totaling over
“It is my pleasure to welcome Nishant to the Jeune team,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics. “As a seasoned finance executive and cross-functional leader with deep capital markets and transactions experience, including in the field of medical aesthetics, Nishant is a great fit for Jeune as we advance our lead program into Phase 2 later this year. I look forward to working with Nishant to unlock the significant value we believe exists in our medical aesthetics pipeline.”
Mr. Saxena brings extensive experience in life sciences, capital markets, and finance to his role as CFO at Jeune. Prior to joining Jeune, Mr. Saxena was a Managing Director in the strategic advisory practice focused on the biopharmaceutical sector at Evercore. In his over 15 years at Evercore, Mr. Saxena led numerous client engagements and advised on mergers and acquisitions, private placements, initial public offerings, follow-on offerings, partnerships, structured financings, and other transactions. Earlier in his career, Mr. Saxena held positions of increasing responsibility in private equity, venture capital, and investment advisory firms. Mr. Saxena received a B.S. in Economics and an MBA from the Wharton School at the University of Pennsylvania.
“I am excited to be joining Jeune as the company embarks on its next stage of growth,” said Mr. Saxena. “With promising KB301 Phase 1 data and a growing, innovative pipeline following closely behind, Jeune is uniquely positioned to meet the strong existing demand for therapies that fundamentally address aged skin. I look forward to working with the talented team at Jeune to drive investment and build a leader in rejuvenative medical aesthetics.”
About KB301
KB301 is an investigational aesthetic therapy employing Krystal’s novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the COL3A1 transgene and increase COL3 levels in skin to address signs of skin aging associated with declining collagen levels and damage of the skin’s extracellular matrix. KB301 is formulated as a solution for direct intradermal injection to aesthetic priority areas.
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit http://www.jeuneinc.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about unlocking the significant value management believes exists in Jeune’s growing and innovative medical aesthetics pipeline; plans to progress Jeune’s lead product into Phase 2 development in 2025; driving investment in Jeune and building a leader in rejuvenative medical aesthetics; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of Jeune’s investigative products, and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s and Jeune’s views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s and Jeune’s views as of any date subsequent to the date of this press release.
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Jeune Aesthetics' new CFO Nishant Saxena start his position at KRYS?
What is the total transaction value Nishant Saxena advised on at Evercore before joining KRYS?
When will Jeune Aesthetics (KRYS) begin Phase 2 trials for their lead program?
What is the current development status of Jeune Aesthetics' KB301 product?
What is Jeune Aesthetics' relationship with Krystal Biotech (KRYS)?
